The Addiction Psychiatry Fellowship curriculum will give you the skills, clinical judgment and knowledge necessary to practice addiction psychiatry to enable you to assume a leadership position in the field.
Your training will give you clinical experience in diagnostic and therapeutic addiction psychiatry with specific skill development in:
- Ability to perform and record from the biopsychosocial and functional perspectives an accurate and comprehensive psychiatric evaluation of the patient with psychoactive substance related disorders.
- Capacity to arrive at a differential diagnosis of all substance related disorders, including abuse, dependence, intoxication, withdrawal, substance-induced mood, anxiety, delirium and psychotic disorders, as well as all other concomitant Axis I and II psychiatric disorders.
- Skills to create comprehensive treatment plans from a biopsychosocial and multidisciplinary perspective for patients with psychoactive substance related disorders.
- Ability to assess and manage patients with psychoactive substance related disorders in the inpatient, intensive outpatient and ambulatory care settings.
- Expertise in utilizing multidisciplinary team members in the development of and execution of the comprehensive treatment plan.
- Experience in the use of a variety of psychotherapeutic techniques for treatment of psychoactive substance dependence, including motivational interviewing, psychoeducation, relapse prevention, and supportive, cognitive-behavioral, psychodynamic, couples, family, and group therapies.
- Adept in intermediate term, individual psychiatric treatment of psychoactive substance dependent outpatients.
- Competence in psychopharmacologic treatment of substance use disorders (including opioid substitution therapy, opioid antagonist therapy, nicotine replacement therapy, relapse prevention, and agents used for medically supervised withdrawal), as well as in psychopharmacologic treatment of co-morbid psychiatric disorders.
|Intensive Addiction Program
||24 weeks; mornings
|Outpatient Addiction Service
||Afternoons; 1 each week
|Pain Rehabilitation Center
||4 weeks; mornings
|Nicotine Dependence Center
||2 weeks; mornings
|Opioid Management Program
||4 weeks; 3 each week
|Continuity Care Clinic
||Afternoons; 2 each week
|Perinatal Mood and Anxiety Disorder Clinic
||Afternoons; 2 each month
||4 weeks; afternoons
|Addiction Transplant Service
||4 weeks; mornings
|Electives and research
||8 weeks; mornings or afternoons
You will participate in and learn to coordinate regular weekly psychiatry conferences. In addition, you will have close contact with the clinical psychiatry services. There will also be opportunities to observe addiction studies with patients and attend various psychiatry and psychology conferences.
Mayo Clinic has established a landmark research program in the genomics of addiction with the long-term goal of predicting and preventing alcoholism and other chemical dependencies.
The first step in the research is to identify human genes that contribute to the individual's vulnerability to alcoholism. The next step will be to develop ways to use the genetic information to protect the patient from becoming addicted. Ultimately, people who are at increased risk of becoming addicted could receive personalized therapy that could change their lives.
To meet its ongoing commitment to provide cutting-edge patient care, the Department of Psychiatry and Psychology at Mayo Clinic is involved with multiple research projects including:
- Electroconvulsive therapy
- Cognitive disorders
- Transcranial magnetic stimulation
- Other neuropsychiatric treatment
- Sleep disorder
- Nicotine dependence
- Eating disorder
- Obsessive-compulsive disorder
Educational opportunities are available in a variety of clinical settings including clinic-and hospital-based outpatient treatment programs, as well as in the consultation-liaison setting.
An additional opportunity is available to learn to treat nicotine dependency in Mayo Clinic's Nicotine Dependence Center. Fellows have an opportunity to participate in ongoing research through the Samuel C. Johnson Genomics of Addiction Program at Mayo Clinic.